• norsk
    • English
  • English 
    • norsk
    • English
  • Login
View Item 
  •   Home
  • Faculty of Medicine
  • Department of Clinical Science
  • Department of Clinical Science
  • View Item
  •   Home
  • Faculty of Medicine
  • Department of Clinical Science
  • Department of Clinical Science
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders

Steen, Nils Eiel; Dieset, Ingrid; Hope, Sigrun; Vedal, Trude Seselie Jahr; Smeland, Olav Bjerkehagen; Matson, Wayne; Kaddurah-Daouk, Rima; Agartz, Ingrid; Melle, Ingrid; Djurovic, Srdjan; Jönsson, Erik Gunnar; Bogdanov, Mikhail; Andreassen, Ole Andreas
Peer reviewed, Journal article
Accepted version
Thumbnail
View/Open
Accepted version (246.9Kb)
URI
https://hdl.handle.net/1956/22366
Date
2020
Metadata
Show full item record
Collections
  • Department of Clinical Science [1114]
Original version
https://doi.org/10.1017/s0033291719000400
Abstract
Background: We aimed at exploring potential pathophysiological processes across psychotic disorders, applying metabolomics in a large and well-characterized sample of patients and healthy controls. Methods: Patients with schizophrenia and bipolar disorders (N = 212) and healthy controls (N = 68) had blood sampling with subsequent metabolomics analyses using electrochemical coulometric array detection. Concentrations of 52 metabolites including tyrosine, tryptophan and purine pathways were compared between patients and controls while controlling for demographic and clinical characteristics. Significant findings were further tested in medication-free subsamples. Results: Significantly decreased plasma concentrations in patients compared to healthy controls were found for 3-hydroxykynurenine (3OHKY, p = 0.0008), xanthurenic acid (XANU, p = 1.5×10−5), vanillylmandelic acid (VMA, p = 4.5×10−5) and metanephrine (MN, p = 0.0001). Plasma concentration of xanthine (XAN) was increased in the patient group (p = 3.5×10−5). Differences of 3OHKY, XANU, VMA and XAN were replicated across schizophrenia spectrum disorders and bipolar disorders subsamples of medication-free individuals. Conclusions: Although prone to residual confounding, the present results suggest the kynurenine pathway of tryptophan metabolism, noradrenergic and purinergic system dysfunction as trait factors in schizophrenia spectrum and bipolar disorders. Of special interest is XANU, a metabolite previously not found to be associated with bipolar disorders.
Publisher
Cambridge University Press
Journal
Psychological Medicine
Copyright
Cambridge University Press 2019

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit
 

 

Browse

ArchiveCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsDocument TypesJournalsThis CollectionBy Issue DateAuthorsTitlesSubjectsDocument TypesJournals

My Account

Login

Statistics

View Usage Statistics

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit